PNPLA3 and fatty liver disease: CRISPR–Cas9 experiments further demonstrated that this interaction drives lipid accumulation and fibrosis, establishing a direct link between ER-α and PNPLA3 p.I148M in the pathogenesis of fatty liver disease in women.